Soren E Bjorn
Overview
Explore the profile of Soren E Bjorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gandhi P, Zivkovic M, Ostergaard H, Bonde A, Elm T, Lovgreen M, et al.
Nat Cardiovasc Res
. 2024 Aug;
3(2):166-185.
PMID: 39196196
Inherited bleeding disorders such as Glanzmann thrombasthenia (GT) lack prophylactic treatment options. As a result, serious bleeding episodes are treated acutely with blood product transfusions or frequent, repeated intravenous administration...
2.
Stennicke H, Kjalke M, Karpf D, Balling K, Johansen P, Elm T, et al.
Blood
. 2013 Jan;
121(11):2108-16.
PMID: 23335368
Frequent infusions of intravenous factor VIII (FVIII) are required to prevent bleeding associated with hemophilia A. To reduce the treatment burden, recombinant FVIII with a longer half-life was developed without...
3.
Persson E, Olsen O, Bjorn S, Ezban M
Semin Thromb Hemost
. 2012 Apr;
38(3):274-81.
PMID: 22510860
Vatreptacog alfa is a genetically engineered variant of recombinant factor VIIa (rFVIIa) containing three amino acid changes. Aspartic acid, valine, and glutamine residues replace valine, glutamic acid, and methionine at...
4.
Ostergaard H, Bjelke J, Hansen L, Petersen L, Pedersen A, Elm T, et al.
Blood
. 2011 Jun;
118(8):2333-41.
PMID: 21700771
Current management of hemophilia B entails multiple weekly infusions of factor IX (FIX) to prevent bleeding episodes. In an attempt to make a longer acting recombinant FIX (rFIX), we have...
5.
Karpf D, Sorensen B, Hermit M, Holmberg H, Tranholm M, Bysted B, et al.
Thromb Res
. 2011 Mar;
128(2):191-5.
PMID: 21429564
Introduction: Bleeding episodes in haemophilia patients with inhibitors are primarily treated with by-passing agents such as recombinant activated FVII (rFVIIa). Prophylactic treatment with rFVIIa has been shown to significantly reduce...
6.
Johansen P, Bjorn S, Agerso H, Thorup I, Hermit M, Sorensen B, et al.
Thromb Haemost
. 2010 Apr;
104(1):157-64.
PMID: 20390231
The pharmacokinetics and pharmacodynamics of 40k-PEG-rFVIIa, a GlycoPEGylated derivative of recombinant wild-type FVIIa, were compared with rFVIIa in rabbits. The procoagulant effect was determined as the weight of the clot...
7.
Stennicke H, Ostergaard H, Bayer R, Kalo M, Kinealy K, Holm P, et al.
Thromb Haemost
. 2008 Nov;
100(5):920-8.
PMID: 18989539
Prophylaxis with 2-4 times weekly dosing of factor (F)VIII or FIX is established as an efficacious and safe treatment in haemophilia. Although prophylaxis is not readily available for the inhibitor...
8.
Kirkeby A, Torup L, Bochsen L, Kjalke M, Abel K, Theilgaard-Monch K, et al.
Thromb Haemost
. 2008 Apr;
99(4):720-8.
PMID: 18392330
The haematopoietic hormone erythropoietin (EPO) has neuroprotective properties and is currently being explored for treatment of stroke and other neurological disorders. Short-term, high-dose treatment with EPO seems to improve neurological...
9.
Petersen L, Albrektsen T, Hjorto G, Kjalke M, Bjorn S, Sorensen B
Thromb Haemost
. 2007 Oct;
98(4):909-11.
PMID: 17938822
No abstract available.
10.
Petersen L, Norby P, Branner S, Sorensen B, Elm T, Stennicke H, et al.
Thromb Res
. 2005 Apr;
116(1):75-85.
PMID: 15850611
Tissue factor (TF) is believed to play an important role in coagulation, inflammation, angiogenesis and wound healing as well as in tumor growth and metastasis. To facilitate in vivo studies...